Study
| Open-label, nonrandomized, phase II basket study |
| Unresectable or metastatic 36 anaplastic thyroid cancer patients |
| Dabrafenib 150 mg x 2 /day plus trametinib 2 mg/day |
Efficacy
| ORR: 56% (95% CI, 38.1% to 72.1%), CR:3 patients |
| 12-month DOR: 50%. |
| mPFS:6.7 m and mOS:14.5 m |
| 12 month PFS and OS: 43.2% and 51.7% |
Safety
| All grades AEs: 75% |
| Serious AEs: 56% |
| Grade ≥3 AEs 58%, anemia:19%, pneumonia:19%, hyponatremia:17% |
Ann Oncol. 2022 Apr;33(4):406-415
http://doi.org/10.1016/j.annonc.2021.12.014
Reviewed by Hasan Cagri Yildirim, MD on Sep 20, 2022
